195 related articles for article (PubMed ID: 36550260)
21. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain.
Ginés S; Bosch M; Marco S; Gavaldà N; Díaz-Hernández M; Lucas JJ; Canals JM; Alberch J
Eur J Neurosci; 2006 Feb; 23(3):649-58. PubMed ID: 16487146
[TBL] [Abstract][Full Text] [Related]
22. Increased Olfactory Bulb BDNF Expression Does Not Rescue Deficits in Olfactory Neurogenesis in the Huntington's Disease R6/2 Mouse.
Smail S; Bahga D; McDole B; Guthrie K
Chem Senses; 2016 Mar; 41(3):221-32. PubMed ID: 26783111
[TBL] [Abstract][Full Text] [Related]
23. CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo.
Monteys AM; Ebanks SA; Keiser MS; Davidson BL
Mol Ther; 2017 Jan; 25(1):12-23. PubMed ID: 28129107
[TBL] [Abstract][Full Text] [Related]
24. Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.
Cowin RM; Roscic A; Bui N; Graham D; Paganetti P; Jankowsky JL; Weiss A; Paylor R
Behav Brain Res; 2012 Apr; 229(2):308-19. PubMed ID: 22306231
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease.
Vachey G; Déglon N
Methods Mol Biol; 2018; 1780():463-481. PubMed ID: 29856031
[TBL] [Abstract][Full Text] [Related]
26. Differential proteomic and genomic profiling of mouse striatal cell model of Huntington's disease and control; probable implications to the disease biology.
Choudhury KR; Das S; Bhattacharyya NP
J Proteomics; 2016 Jan; 132():155-66. PubMed ID: 26581643
[TBL] [Abstract][Full Text] [Related]
27. Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.
Chaturvedi RK; Hennessey T; Johri A; Tiwari SK; Mishra D; Agarwal S; Kim YS; Beal MF
Hum Mol Genet; 2012 Aug; 21(15):3474-88. PubMed ID: 22589249
[TBL] [Abstract][Full Text] [Related]
28. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
29. Lack of RAN-mediated toxicity in Huntington's disease knock-in mice.
Yang S; Yang H; Huang L; Chen L; Qin Z; Li S; Li XJ
Proc Natl Acad Sci U S A; 2020 Feb; 117(8):4411-4417. PubMed ID: 32029588
[TBL] [Abstract][Full Text] [Related]
30. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism.
Spires TL; Grote HE; Varshney NK; Cordery PM; van Dellen A; Blakemore C; Hannan AJ
J Neurosci; 2004 Mar; 24(9):2270-6. PubMed ID: 14999077
[TBL] [Abstract][Full Text] [Related]
31. PGC-1α rescues Huntington's disease proteotoxicity by preventing oxidative stress and promoting TFEB function.
Tsunemi T; Ashe TD; Morrison BE; Soriano KR; Au J; Roque RA; Lazarowski ER; Damian VA; Masliah E; La Spada AR
Sci Transl Med; 2012 Jul; 4(142):142ra97. PubMed ID: 22786682
[TBL] [Abstract][Full Text] [Related]
32. Introducing an Expanded Trinucleotide Repeat Tract into the Human Genome for Huntington's Disease Modeling In Vitro.
Malankhanova T; Sorokin M; Medvedev S; Zakian S; Malakhova A
Curr Protoc Hum Genet; 2020 Jun; 106(1):e100. PubMed ID: 32469433
[TBL] [Abstract][Full Text] [Related]
33. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number.
Rossignol J; Fink KD; Crane AT; Davis KK; Bombard MC; Clerc S; Bavar AM; Lowrance SA; Song C; Witte S; Lescaudron L; Dunbar GL
Stem Cell Res Ther; 2015 Feb; 6(1):9. PubMed ID: 25971780
[TBL] [Abstract][Full Text] [Related]
34.
McLean ZL; Gao D; Correia K; Roy JCL; Shibata S; Farnum IN; Valdepenas-Mellor Z; Rapuru M; Morini E; Ruliera J; Gillis T; Lucente D; Kleinstiver BP; Lee JM; MacDonald ME; Wheeler VC; Pinto RM; Gusella JF
bioRxiv; 2023 Jul; ():. PubMed ID: 37547003
[TBL] [Abstract][Full Text] [Related]
35. Base editing strategies to convert CAG to CAA diminish the disease-causing mutation in Huntington's disease.
Choi DE; Shin JW; Zeng S; Hong EP; Jang JH; Loupe JM; Wheeler VC; Stutzman HE; Kleinstiver BP; Lee JM
bioRxiv; 2023 Apr; ():. PubMed ID: 37162872
[TBL] [Abstract][Full Text] [Related]
36. Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter.
Martin E; Betuing S; Pagès C; Cambon K; Auregan G; Deglon N; Roze E; Caboche J
Hum Mol Genet; 2011 Jun; 20(12):2422-34. PubMed ID: 21493629
[TBL] [Abstract][Full Text] [Related]
37. Expression of the Huntington's disease transgene in neural stem cell cultures from R6/2 transgenic mice.
Chu-LaGraff Q; Kang X; Messer A
Brain Res Bull; 2001 Oct-Nov 1; 56(3-4):307-12. PubMed ID: 11719265
[TBL] [Abstract][Full Text] [Related]
38. Cell-Specific Deletion of PGC-1α from Medium Spiny Neurons Causes Transcriptional Alterations and Age-Related Motor Impairment.
McMeekin LJ; Li Y; Fox SN; Rowe GC; Crossman DK; Day JJ; Li Y; Detloff PJ; Cowell RM
J Neurosci; 2018 Mar; 38(13):3273-3286. PubMed ID: 29491012
[TBL] [Abstract][Full Text] [Related]
39. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
